Radiopharm Theranostics Ltd (ASX:RAD) and partner Targeted Radiopharmaceuticals In Molecular Theranostics (TRIMT) GmbH are preparing to present on Ga68-Integrin (RAD301), which targets pancreatic cancer, at the 35th Annual Congress of the European Association of Nuclear Medicine (EANM).
EANM is held once a year and is a key meeting of nuclear medicine physicians, physicists, radiopharmacists, radiochemists and other science and health professionals from Europe and around the world.
Global footprint
The conference is well supported by a raft of industrial exhibitors with global footprint.
Dr Jana Rehm, of the University Hospital Carl Gustav Carus Dresden’s Nuclear Medicine department, will present on the first clinical experience of PET/CT and PET/MR imaging with 68Ga-TVH in patients with pancreatic cancer within one of the top-rated oral presentation sessions of the Scientific Program of EANM.
The lecture will be given on Tuesday, October 18, in a session looking at new radiopharmaceutical trials.
In other good news, the clinical evaluation of Ga68-Integrin in PDAC by the team of Professor Dr Jörg Kotzerke was also selected for the congress’ highlights.
Significant endorsement
“We’re thrilled to see this independent endorsement highlighting the significance of our Trivehexin technology at a major radiopharmaceutical meeting, and we look forward to reporting continued progress of the program,” said TRIMT CEO and co-founder Dr Jakub Simecek.
“It is a pleasure to see the excellent work of the medical team from Dresden receive this recognition by the EANM committee for their first translation of TRIMT´s Trivehexin (RAD301) in the clinical setup,” said Radiopharm Theranostics CEO and managing director Riccardo Canevari.
Radiopharm Theranostics and TRIMT entered into an exclusive licence agreement in August 2021 to develop radiopharmaceuticals including Ga68-Integrin (RAD301).